0

Amiodarone: very low dose to maintain sinus rhythm

Amiodarone: very low dose to maintain sinus rhythm, Antiarrhythmic versus control: study Excluded of the Systematic review

Antiarrhythmic versus antiarrhythmic: study Excluded of the Systematic review

Antiarrhythmic versus antiarrhythmic: study Included in the Systematic review

Antiarrhythmic versus both Control and Antiarrhythmic: study Excluded of the systematic review

Antiarrhythmic versus both Control and Antiarrhythmic: study Included in the Systematic review

Antiarrhythmic versus Control: study awaiting assesment

Antiarrhythmic versus control: study Excluded of the Systematic review

Antiarrhythmic versus control: study Included in the Systematic review

Antiarrthythmic drugs: Amiodarone: Adverse effects

Antiarrthythmic drugs: Amiodarone: Pharmacokinetics

Atrial fibrillation in patients undergoing heart surgery: Amiodarone for prevention

Atrial fibrillation: angiotensin system blockers for prevention of new-onset atrial fibrillation

Atrial fibrillation: angiotensin system blockers to reduce recurrences after cardioversion

Atrial fibrillation: angiotensin sytem blockers to reduce cardiovascular events

Atrial fibrillation: Circumferential Pulmonary-vein Catheter Ablation for treatment

Atrial fibrillation: clinical practice guidelines

Atrial fibrillation: Cost-effectiveness and Decision analysis studies

Atrial fibrillation: Cost-effectiveness and Decision analysis studies / Atrial fibrillation: Circumferential Pulmonary-vein Catheter Ablation

Atrial fibrillation: Cost-effectiveness and Decision analysis studies / Atrial fibrillation: Rhythm control versus rate control strategy

Atrial fibrillation: new Oral anticoagulants for preventing stroke and embolism

Atrial fibrillation: Risk stratification schemes for predicting stroke and embolism

Atrial fibrillation: Risk stratification schemes for predicting stroke and embolism, Elder patients

Atrial fibrillation: spontaneous Recurrence rate after electrical or pharmacological cardioversion

Background

Background / Atrial fibrillation: clinical practice guidelines

Background, others

Background, study

Drugs for rate control

Meta-analysis: Antiarrhythmic versus antiarrhythmic

Meta-analysis: Antiarrhythmic versus control

Meta-analysis: Drug cardioversion

Meta-analysis: Rhythm control versus rate control

Rhythm control versus rate control

Rhythm control versus rate control, Antiarrhythmic versus control: study Excluded of the Systematic review

working cost-effectiveness study: data sources: studies included as data source / Meta-analysis: Rhythm control versus rate control

working cost-effectiveness study: data sources: studies included as data sources

working cost-effectiveness study: data sources: studies included as data sources / Antiarrthythmic drugs: Amiodarone: Adverse effects

working cost-effectiveness study: data sources: studies included as data sources / Meta-analysis: Antiarrhythmic versus control

working cost-effectiveness study: data sources: studies included as data sources / Meta-analysis: Drug cardioversion

working cost-effectiveness study: data sources: studies NOT included

working cost-effectiveness study: data sources: studies NOT included / Meta-analysis: Antiarrhythmic versus antiarrhythmic

working cost-effectiveness study: data sources: studies NOT included / Meta-analysis: Antiarrhythmic versus control

working cost-effectiveness study: data sources: studies NOT included / Meta-analysis: Drug cardioversion